Centre to cap profit margins on non-scheduled cancer drugs at 30%

The central government has announced plans to impose a ceiling of 30 percent on trade margins for non-scheduled cancer medications, a significant intervention aimed at controlling drug prices in the oncology segment. The regulatory cap is projected to substantially lower maximum retail prices, with potential reductions reaching as high as 70 percent in certain cases, according to official assessments.

The price regulation is expected to deliver cumulative annual savings of approximately ₹2,500 crore to patients across the country who depend on cancer treatments. Non-scheduled drugs—those not included in the government's price control regime—have emerged as a particular concern due to their relatively unregulated pricing mechanisms, leading to steep patient expenditures.

The move aligns with mounting judicial scrutiny of pharmaceutical pricing practices. The Supreme Court has been examining allegations that manufacturers and distributors have been applying excessive mark-ups on essential cancer medications, effectively pricing life-saving treatments beyond the reach of many patients.

The government's decision reflects an effort to balance industry interests with public health imperatives, bringing non-scheduled cancer drugs within a defined margin framework. The 30 percent cap applies to the profit margins across the supply chain, from manufacturers through distribution channels to retail outlets.

Industry observers note that the measure represents a significant policy shift in drug price regulation, potentially setting a precedent for other therapeutic categories. The implementation timeline and specific operational mechanisms for enforcement remain subjects of further clarification by health authorities.